ANI Pharmaceuticals Cost of Revenue 2011-2026 | ANIP

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue ANI Pharmaceuticals

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
250 M	182 M	139 M	101 M	87.2 M	63.2 M	73 M	79 M	48.8 M	12.7 M	11.5 M	9.97 M	9.17 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
250 M	9.17 M	82 M

Quarterly Cost of Revenue ANI Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
93.4 M	74.6 M	73 M	63.1 M	57.7 M	49.2 M	48.1 M	42.3 M	37.7 M	-	32.9 M	35.3 M	34.3 M	-	24.4 M	22.3 M	20 M	-	20.1 M	20.7 M	21.8 M	-	15 M	15.6 M	14.7 M	-	15.6 M	16.6 M	20.7 M	-	21.1 M	21.1 M	16.4 M	-	16.7 M	11.8 M	3.41 M	-	3.26 M	3.14 M	2.75 M	-	3.06 M	2.12 M	2.62 M	-	2.71 M	2.17 M	2.41 M	-	2.32 M	2.12 M	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
93.4 M	2.12 M	24.1 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	32.2 M	-	2.43 %	$ 254 M	Germany
Aeterna Zentaris AEZS	90 K	-	5.93 %	$ 314 M	Canada
Acorda Therapeutics ACOR	15.3 M	-	-24.86 %	$ 820 K	USA
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
Aytu BioScience AYTU	20.6 M	$ 2.71	1.88 %	$ 17 M	USA
Amphastar Pharmaceuticals AMPH	358 M	$ 25.87	-0.79 %	$ 1.25 B	USA
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
BeiGene, Ltd. BGNE	70.7 M	-	0.49 %	$ 251 B	Cayman-islands
Ascendis Pharma A/S ASND	3.52 M	$ 215.29	4.59 %	$ 5 B	Danmark
BioNTech SE BNTX	2.91 B	$ 105.97	-2.78 %	$ 27.2 B	Germany
Bellicum Pharmaceuticals BLCM	436 K	-	-9.72 %	$ 5.89 M	USA
Acasti Pharma ACST	76 K	-	4.01 %	$ 150 M	Canada
Baudax Bio BXRX	7.01 M	-	0.59 %	$ 63 K	USA
Arrowhead Pharmaceuticals ARWR	17.3 M	$ 64.74	1.41 %	$ 8.66 B	USA
CASI Pharmaceuticals CASI	12.6 M	$ 0.95	-0.72 %	$ 129 M	USA
Ayala Pharmaceuticals AYLA	602 K	-	-	$ 7.46 M	Israel
Celldex Therapeutics CLDX	200 K	$ 25.15	-1.95 %	$ 1.62 M	USA
AIkido Pharma AIKI	9 K	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	1.36 M	-	-0.23 %	$ 916 M	USA
CureVac N.V. CVAC	238 M	-	-	$ 867 M	Germany
Catalyst Biosciences CBIO	4.64 M	$ 14.01	3.7 %	$ 922 M	USA
Ampio Pharmaceuticals AMPE	369 K	-	-11.43 %	$ 502 K	USA
Biogen BIIB	2.31 B	$ 164.87	0.27 %	$ 24 B	USA
Avid Bioservices CDMO	133 M	-	-	$ 789 M	USA
BioVie BIVI	312 K	$ 1.23	2.07 %	$ 1.82 M	USA
Catalyst Pharmaceuticals CPRX	68.8 M	$ 23.32	2.71 %	$ 2.76 B	USA